semaglutide compounded claims withdrawn Despite FDA ruling, GLP-1s are still giving Novo and Lilly headaches on the market semaglutide compounder claims withdrawn Drugmakers

While these drugs are designed for long-term use in disease management, many individuals use GLP-1s for a limited periodeither to jump-start weight loss before transitioning to a lifestyle-based maintenance or due to financial constraints

Of note, people with type 2 diabetes had a lower mean percentage weight loss at the 3-month mark compared with those without type 2 diabetes: 3.9% in those with type 2 diabetes vs 6.3% in those without type 2 diabetes

Any use outside of clinical trials carries significant risks, and individuals should consult a qualified healthcare provider before considering such use

Last May, he went to see an endocrinologist, and things have been going well since

The STEP trials for semaglutide 2.4 mg in weight management showed mean weight loss of 14.9% from baseline at 68 weeks